Urinary Retention

Approved for this indication (1)

• bethanechol

Phase 4 trials (4)

• tamsulosin
• phenazopyridine
• magnesium sulfate
• morphine

Phase 3 trials (3)

• alfuzosin
• rimabotulinumtoxinB
• glucose

Phase 2 trials (1)

• tranexamic acid

Phase 1 trials (2)

• donepezil
• autologous muscle derived stem cells

Other trials (8)

• paraffin oil
• prazosin
• dutasteride
• levobupivacaine
• terazosin
• fentanyl
• doxazosin
• peppermint extract

Organization Involved with Phase 4 Indications (13)

• GlaxoSmithKline
• University of Pittsburgh
• Memorial Health University Medical Center
• Tufts University
• University of Bern
• Wake Forest University
• Genesys Regional Medical Center
• Kantonsspital Graubünden
• University of Cincinnati
• Icahn School of Medicine at Mount Sinai
• Allegheny Health Network
• Kantonsspital Baden
• Becton Dickinson

Organization Involved with Phase 3 Indications (10)

• Sanofi
• Case Western Reserve University
• University of London
• McMaster University
• Seoul National University
• University of Michigan
• Mayo Clinic
• University of Massachusetts
• University of Wisconsin
• University of Paris

Organization Involved with Phase 2 Indications (9)

• Boehringer Ingelheim
• Fraser Health
• Johns Hopkins University
• University of Thessaly
• Laval University
• Tel Aviv University
• TriHealth
• Hackensack University Medical Center
• Michael Smith Foundation for Health Research

Organization Involved with Phase 1 Indications (5)

• United States Army
• Oakland University
• National University of Singapore
• The Cleveland Clinic
• Beaumont Hospital, Dublin 9, Ireland

Organization Involved with Other Experimental Indications (7)

• Franklin D. Gaylis, MD Inc.
• Cedars-Sinai Medical Center
• Radboud University
• Rijnstate Hospital
• University of Rochester
• Chinese University of Hong Kong
• Government of Hong Kong